Anti-IN01 antibodies significantly improve the activity of RET, BRAF, MEK and PI3K kinase inhibitors in preclinical models
We have recently shown that anti-IN01 antibodies having functionality to recognize EGF potentiate the effects of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor mutant (EGFR-mut) cell lines (1). As a result, a Phase I/II clinical trial of anti-IN01 antibodies in combination with afatinib has been initiated.